PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsProgesterone
Progesterone
Bijuva, Crinone, Endometrin, Progesterone, Prometrium (progesterone) is a small molecule pharmaceutical. Progesterone was first approved as Progesterone on 1982-01-01. It is used to treat amenorrhea, endometrial hyperplasia, female infertility, and uterine hemorrhage in the USA. The pharmaceutical is active against progesterone receptor. In addition, it is known to target short transient receptor potential channel 5, cation channel sperm-associated protein 1, cation channel sperm-associated protein 4, mineralocorticoid receptor, cation channel sperm-associated protein 2, and cation channel sperm-associated protein 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Crinone, Endometrin, Prometrium (generic drugs available since 2001-04-25, discontinued: Milprosa, Progestasert)
Combinations
Bijuva
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Estradiol
+
Progesterone
Tradename
Company
Number
Date
Products
BIJUVAMayne GroupN-210132 RX2018-10-28
2 products, RLD, RS
Progesterone
Tradename
Company
Number
Date
Products
CRINONEAllerganN-020701 RX1997-07-31
2 products, RLD, RS
ENDOMETRINFerring PharmaceuticalsN-022057 RX2007-06-21
1 products, RLD, RS
PROMETRIUMVirtus PharmaceuticalsN-019781 RX1998-05-14
2 products, RLD
Show 5 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
advanced formula progesto-lifeunapproved drug other2022-03-31
bijuvaNew Drug Application2023-12-07
crinoneNew Drug Application2019-01-16
endometrinNew Drug Application2022-08-16
estradiol and progesteroneANDA2022-03-29
ferring pharmaceuticals inc.New Drug Application2021-07-15
fluocinolone acetonide 0.01% / minoxidil 7% / progesterone 0.1%unapproved drug other2019-05-08
minoxidil 5% / progesterone 0.1% / tretinoin 0.025%unapproved drug other2019-05-06
minoxidil 7% / progesterone 0.1%unapproved drug other2019-04-24
minoxidil 7% / progesterone 0.1% / tretinoin 0.025%unapproved drug other2019-05-06
Show 8 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
amenorrhea—D000568N91.2
endometrial hyperplasia—D004714N85.0
female infertilityEFO_0008560D007247N97
uterine hemorrhage—D014592—
Agency Specific
FDA
EMA
Expiration
Code
PROGESTERONE, MILPROSA, FERRING PHARMS INC
2023-04-29NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Estradiol / Progesterone, Bijuva, Mayne Pharma
86331782032-11-21DP
88466482032-11-21U-2439
88466492032-11-21DPU-2439
89330592032-11-21DPU-2439
89872372032-11-21DP
89935482032-11-21DP
89935492032-11-21DP
90062222032-11-21DPU-2439
91141452032-11-21U-2439
91141462032-11-21DPU-2439
93019202032-11-21DPU-2439
100523862032-11-21DP
102069322032-11-21U-2439
106393752032-11-21DP
106752882032-11-21U-2439
108067402032-11-21DPU-2439
110336262032-11-21DPU-2439
111035132032-11-21U-2439
111035162032-11-21DP
111100992032-11-21DP
111669632032-11-21DP
115293602032-11-21DP
Progesterone, Milprosa, Ferring Pharms Inc
85802932030-01-21U-2810
105375842029-02-03DP
105489042029-02-03U-2810
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03D: Progestogen sex hormones and modulators of the genital system
— G03DA: Pregnen (4) derivatives, progestogens
— G03DA04: Progesterone
— G03F: Progestogens and estrogens in combination
— G03FA: Progestogens and estrogens, fixed combinations
— G03FA04: Progesterone and estrogen
— G03X: Other sex hormones and modulators of the genital system in atc
— G03XB: Progesterone receptor modulators, sex hormones and modulators of the genital system
HCPCS
Code
Description
J1050
Injection, medroxyprogesterone acetate, 1 mg
J1726
Injection, hydroxyprogesterone caproate, (makena), 10 mg
J1729
Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
J2675
Injection, progesterone, per 50 mg
S3620
Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total)
Clinical
Clinical Trials
1256 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfertilityD007246HP_0000789—915274580172
Breast neoplasmsD001943EFO_0003869C50157031137143
ContraceptionD003267——101512142978
Premature birthD047928EFO_0003917O601112163061
Female infertilityD007247EFO_0008560N9743883252
Polycystic ovary syndromeD011085EFO_0000660E28.254661838
EndometriosisD004715EFO_0001065N80110741532
MenopauseD008593EFO_0003922N9538613431
PregnancyD011247EFO_0002950Z33.132451630
Premature obstetric laborD007752—O6024291127
Show 86 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD064726——561—210
Coronary diseaseD003327————7—310
Heart diseasesD006331EFO_0003777I51.9——6—39
Anorexia nervosaD000856EFO_0004215F50.0143——6
Myocardial ischemiaD017202EFO_1001375I20-I25——5——5
Cocaine-related disordersD019970—F14111—35
Pelvic painD017699———22—14
PainD010146EFO_0003843R52—12—14
Alzheimer diseaseD000544EFO_0000249F03—22—14
Traumatic brain injuriesD000070642—S06211—14
Show 37 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperandrogenismD017588——31——48
NeoplasmsD009369—C8032——26
Placenta previaD010923EFO_0007442O44—1——34
Non-small-cell lung carcinomaD002289———2——13
Male breast neoplasmsD018567———1——23
Myeloid leukemia acuteD015470—C92.012———2
Colorectal neoplasmsD015179——22———2
Neoplasm metastasisD009362EFO_0009708——2———2
Premature menopauseD008594HP_0008209E28.3111——12
Bipolar disorderD001714EFO_0000289F30.9—1——12
Show 50 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD010599——4———15
PubertyD011627EFO_0001382—2———13
Postcoital contraceptionD044363——1———12
Menstruation disturbancesD008599HP_0400007N91.52————2
Intracytoplasmic sperm injectionsD020554——1———12
Urogenital abnormalitiesD014564——1————1
Biological availabilityD001682——1————1
Migraine disordersD008881EFO_0003821G431————1
InfectionsD007239EFO_0000544—1————1
Prostatic neoplasmsD011471—C611————1
Show 11 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Menstrual cycleD008597——————77
ObesityD009765EFO_0001073E66.9————44
Metabolic syndromeD024821EFO_0000195E88.810————33
Circadian rhythmD002940EFO_0004354—————22
Heart disease risk factorsD000082742——————22
Oocyte donationD018587——————22
Ectopic pregnancyD011271—O00————22
Depressive disorderD003866EFO_1002014F32.A————22
Hormonal contraceptionD000080282——————22
Luteal phaseD008183——————22
Show 65 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameProgesterone
INNprogesterone
Description
Progesterone is a C21-steroid hormone in which a pregnane skeleton carries oxo substituents at positions 3 and 20 and is unsaturated at C(4)-C(5). As a hormone, it is involved in the female menstrual cycle, pregnancy and embryogenesis of humans and other species. It has a role as a contraceptive drug, a progestin, a progesterone receptor agonist, a human metabolite and a mouse metabolite. It is a 20-oxo steroid, a 3-oxo-Delta(4) steroid and a C21-steroid hormone. It derives from a hydride of a pregnane.
Classification
Small molecule
Drug classprogestins; steroids (androgens, anabolics); antiandrogens
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Identifiers
PDB—
CAS-ID57-83-0
RxCUI—
ChEMBL IDCHEMBL103
ChEBI ID17026
PubChem CID5994
DrugBankDB00396
UNII ID4G7DS2Q64Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
NR3C2
NR3C2
CATSPER2
CATSPER2
NCOA2
NCOA2
Organism
Homo sapiens
Gene name
NR3C2
Gene synonyms
MCR, MLR
NCBI Gene ID
4306
Protein name
mineralocorticoid receptor
Protein synonyms
aldosterone receptor, mineralocorticoid receptor 1, mineralocorticoid receptor 2, mineralocorticoid receptor delta, Nuclear receptor subfamily 3 group C member 2
Uniprot ID
Q96KQ9
Mouse ortholog
Nr3c2 (110784)
mineralocorticoid receptor (Q8VII8)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Crinone – Juniper Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Bijuva – TherapeuticsMD
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Progesterone
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 175,946 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bijuva, Estradiol and progesterone, Progesterone, Prometrium
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
40,194 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use